Orfiril Retard (Sodium Valproate)

Sodium Valproate, the active ingredient in Orfiril Retard, is an anticonvulsant presented as an extended‑release tablet for oral use. It treats generalized and focal seizures, stabilises mood in bipolar disorder and is used for migraine prophylaxis in adults. GNH USA supplies Orfiril Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Orfiril Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orfiril Retard is an antiepileptic medication that acts on neuronal excitability in several neurological and psychiatric conditions.

- Epilepsy: Reduces the frequency and severity of generalized and focal seizures. - Bipolar disorder: Provides mood stabilization and helps prevent manic episodes. - Migraine prophylaxis: Decreases the number of migraine attacks when used as preventive therapy.

Adverse reactions to Orfiril Retard vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Tremor - Weight gain - Hair loss - Drowsiness - Elevated liver enzymes

Serious or Rare Side Effects: - Severe liver injury - Pancreatitis - Thrombocytopenia - Hyperammonemia - Stevens‑Johnson syndrome - Fatal brain edema

When prescribing Orfiril Retard, clinicians should consider several safety aspects.

- Monitor liver function: Regular blood tests are required to detect hepatotoxicity. - Assess blood counts: Periodic complete‑blood‑count monitoring helps identify thrombocytopenia. - Evaluate pancreatic enzymes: Check amylase and lipase if abdominal symptoms arise. - Review psychiatric history: Monitor for mood changes or depressive symptoms. - Avoid use in pregnancy: Contra‑indicated due to teratogenic risk (Category X). - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Orfiril Retard can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Carbamazepine: Increases valproate clearance, reducing efficacy. - Phenytoin: Reduces valproate plasma levels and may precipitate seizures. - Rifampicin: Strong enzyme inducer that markedly lowers valproate concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: Valproate may enhance anticoagulant effect, requiring INR monitoring. - Oral contraceptives: May reduce hormonal efficacy, increasing risk of breakthrough bleeding. - Lamotrigine: Valproate raises lamotrigine levels, heightening risk of skin reactions.